Cargando…

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD

Creutzfeldt–Jakob disease and Alzheimer's disease are characterized by the presence of elevated total‐Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ermann, Natalia, Lewczuk, Piotr, Schmitz, Matthias, Lange, Peter, Knipper, Tobias, Goebel, Stefan, Kornhuber, Johannes, Zerr, Inga, Llorens, Franc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043772/
https://www.ncbi.nlm.nih.gov/pubmed/30009207
http://dx.doi.org/10.1002/acn3.584
_version_ 1783339352552636416
author Ermann, Natalia
Lewczuk, Piotr
Schmitz, Matthias
Lange, Peter
Knipper, Tobias
Goebel, Stefan
Kornhuber, Johannes
Zerr, Inga
Llorens, Franc
author_facet Ermann, Natalia
Lewczuk, Piotr
Schmitz, Matthias
Lange, Peter
Knipper, Tobias
Goebel, Stefan
Kornhuber, Johannes
Zerr, Inga
Llorens, Franc
author_sort Ermann, Natalia
collection PubMed
description Creutzfeldt–Jakob disease and Alzheimer's disease are characterized by the presence of elevated total‐Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho‐Tau epitopes (non‐P‐Tau) in the discrimination between both diseases. Non‐P‐Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt–Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total‐Tau (90%), P‐Tau (62%) and 14‐3‐3 (91%).
format Online
Article
Text
id pubmed-6043772
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60437722018-07-15 CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD Ermann, Natalia Lewczuk, Piotr Schmitz, Matthias Lange, Peter Knipper, Tobias Goebel, Stefan Kornhuber, Johannes Zerr, Inga Llorens, Franc Ann Clin Transl Neurol Brief Communications Creutzfeldt–Jakob disease and Alzheimer's disease are characterized by the presence of elevated total‐Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho‐Tau epitopes (non‐P‐Tau) in the discrimination between both diseases. Non‐P‐Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt–Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total‐Tau (90%), P‐Tau (62%) and 14‐3‐3 (91%). John Wiley and Sons Inc. 2018-05-26 /pmc/articles/PMC6043772/ /pubmed/30009207 http://dx.doi.org/10.1002/acn3.584 Text en © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communications
Ermann, Natalia
Lewczuk, Piotr
Schmitz, Matthias
Lange, Peter
Knipper, Tobias
Goebel, Stefan
Kornhuber, Johannes
Zerr, Inga
Llorens, Franc
CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
title CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
title_full CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
title_fullStr CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
title_full_unstemmed CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
title_short CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
title_sort csf nonphosphorylated tau as a biomarker for the discrimination of ad from cjd
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043772/
https://www.ncbi.nlm.nih.gov/pubmed/30009207
http://dx.doi.org/10.1002/acn3.584
work_keys_str_mv AT ermannnatalia csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd
AT lewczukpiotr csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd
AT schmitzmatthias csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd
AT langepeter csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd
AT knippertobias csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd
AT goebelstefan csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd
AT kornhuberjohannes csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd
AT zerringa csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd
AT llorensfranc csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd